As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...
Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.
Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...
Ore Huiying / Bloomberg / Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales ...
Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...